{
  "challenge": {
    "id": 8,
    "name": "Brain Cancer Predictive Modeling and Biomarker Discovery Challenge",
    "description": "An estimated 86,970 new cases of primary brain and other central nervous system tumors are expected to be diagnosed in the US in 2019. Brain tumors comprise a particularly deadly subset of all cancers due to limited treatment options and the high cost of care. Clinical investigators at Georgetown University are seeking to advance precision medicine techniques for the prognosis and treatment of brain tumors through the identification of novel multi-omics biomarkers. In support of this goal, precisionFDA and the Georgetown Lombardi Comprehensive Cancer Center and The Innovation Center for Biomedical Informatics at Georgetown University Medical Center (Georgetown-ICBI) are launching the Brain Cancer Predictive Modeling and Biomarker Discovery Challenge! This challenge will ask participants to develop machine learning and/or artificial intelligence models to identify biomarkers and predict patient outcomes using gene expression, DNA copy number, and clinical data. ",
    "meta": {
      "regions": {
        "intro": "\u003ch2 class=\"text-center\"\u003e\n    The Challenge Phase 1 Deadline Has Been Extended to February 5th!\n\u003c/h2\u003e\n\u003cp\u003e\n    Phase 2 data will now be released February 7th and the challenge will close February 14th.\n\u003c/p\u003e\n\u003cp\u003e\n    \u003cb\u003eIn addition to the challenge extension, we’ve added an incentive for the the top three performing teams. These teams or individuals will be awarded a podium presentation and a poster at the \u003ca href=\"https://guevents.georgetown.edu/event/the_annual_big_data_in_biomedicine_symposium#.Xi9DsMhKiUk\"\u003e9th Annual Health Informatics and Data Science Symposium\u003c/a\u003e\u0026nbsp;and will have their registration fees waived. This conference is a great opportunity to meet and network with thought leaders in the fields of precision and molecular medicine, health data analytics, and bioinformatics.\u003c/b\u003e\n\u003c/p\u003e\n\u003cp\u003e\n    \u003cb\u003eIn addition , when applicable, publication authorship byline(s) will be awarded to the top-performing Challenge Team(s) in good standing (i.e., that submit and make publicly available their final Entry(ies) and any write-up, code or other requirement of a particular Challenge). With respect to the Top performing Team(s), only the names of the registered Team Members and any affiliated Lab Head or Principal Investigator will be listed as co-authors in the byline of the Challenge publication. Challenge organizers reserve the right to organize the publication authorship and contribution list.\u003c/b\u003e\n\u003c/p\u003e\n\u003cp\u003e\n    Note: If you choose to use this use this extension to improve upon their model, please include a note in your re-submission.\n\u003c/p\u003e\n\u003cp\u003e\n    \n\u003c/p\u003e\n\u003cp class=\"text-center\"\u003e\n    Challenge Time Period\u003cbr\u003eNovember 1, 2019 through February 14, 2020\n\u003c/p\u003e\n\u003ch2\u003e\n    BACKGROUND\n\u003c/h2\u003e\n\u003cp\u003e\n    An estimated 86,970 new cases of primary brain and other central nervous system tumors are expected to be diagnosed in the US in 2019. Brain tumors comprise a particularly deadly subset of all cancers due to limited treatment options and the high cost of care.\u0026nbsp;Only a few prognostic and predictive markers have been successfully implemented in the clinic so far for gliomas, the most common malignant brain tumor type. These markers include MGMT promoter methylation in high-grade astrocytomas, co-deletion of 1p/19q in oligodendrogliomas, and mutations in IDH1 or IDH2 genes (Staedtke et al. 2016). There remains significant potential for identifying new clinical biomarkers in gliomas.\n\u003c/p\u003e\n\u003cp\u003e\n    Clinical investigators at Georgetown University are seeking to advance precision medicine techniques for the prognosis and treatment of brain tumors through the identification of novel multi-omics biomarkers. In support of this goal, precisionFDA and the Georgetown Lombardi Comprehensive Cancer Center and The Innovation Center for Biomedical Informatics at Georgetown University Medical Center are launching the Brain Cancer Predictive Modeling and Biomarker Discovery Challenge! This challenge asks participants to develop machine learning and/or artificial intelligence models to identify biomarkers and predict patient outcomes using gene expression, DNA copy number, and clinical data.\n\u003c/p\u003e\n\u003ch2\u003e\n    CHALLENGE OVERVIEW\n\u003c/h2\u003e\n\u003cp\u003e\n    The Brain Cancer Predictive Modeling and Biomarker Discovery Challenge will launch on November 1, 2019 and end on February 14, 2020. Participants are asked to take part in three sub-challenges, which will be scored individually and combined for an overall challenge score. Participants will be provided DNA copy number data, gene expression profiles, clinical phenotypes, and outcomes for a cohort of patients in two phases. The Phase 1 data is the “provided” data that will be used to develop the models. Phase 2 data is the test data that will be used to score model performance. Phase 2 data will be released a week before the final deadline.\n\u003c/p\u003e\n\u003cp\u003e\n    Participants are encouraged to utilize the phenotype data in addition to DNA copy number data and gene expression profiles for each sub-challenge. Participants are also encouraged to employ feature selection to minimize the features used while maintaining performance. A complete challenge submission will include predictions from each sub-challenge on the Phase 2 data, comprehensive documentation of methods employed and datasets used, and code developed for the challenge.\n\u003c/p\u003e\n\u003cimg height=\"890\" src=\"https://dl.dnanex.us/F/D/PVY7KXpkk5jbyjqGkqV2G63kZPVfx2Zgzzf4F1k5/18766648-A5B4-4FE1-96B4-F1E5549518D4-4333-00000316371214C2%20(1).PNG?inline\" width=\"1000\"\u003e\n\u003ch2\u003e\n    CHALLENGE DATA\n\u003c/h2\u003e\n\u003cp\u003e\n    \u003cb\u003eDescriptions\u003c/b\u003e\n\u003c/p\u003e\n\u003cul\u003e\n    \u003cli\u003e\n        DNA copy number\n        \u003cul\u003e\n            \u003cli\u003e\n                Rows are samples\n            \u003c/li\u003e\n            \u003cli\u003e\n                Columns are genomic cytobands\n            \u003c/li\u003e\n            \u003cli\u003e\n                Values are reported as chromosome instability values (CIN Index) (Song et al. 2017) index values at the cytoband level. 0 indicates no instability\n            \u003c/li\u003e\n            \u003cli\u003e\n                Source: SNP array\n            \u003c/li\u003e\n        \u003c/ul\u003e\n    \u003c/li\u003e\n    \u003cli\u003e\n        Gene expression profiles\n        \u003cul\u003e\n            \u003cli\u003e\n                Rows are samples\n            \u003c/li\u003e\n            \u003cli\u003e\n                Columns are gene names\n            \u003c/li\u003e\n            \u003cli\u003e\n                Values are log2 normalized gene expression values\n            \u003c/li\u003e\n            \u003cli\u003e\n                Source: microarray\n            \u003c/li\u003e\n        \u003c/ul\u003e\n    \u003c/li\u003e\n    \u003cli\u003e\n        Survival status outcome\n        \u003cul\u003e\n            \u003cli\u003e\n                A value of 0 means the patient was\u0026nbsp;\u003ci\u003ealive or censoring\u003c/i\u003e at last follow up\n            \u003c/li\u003e\n            \u003cli\u003e\n                A value of 1 means patient\u0026nbsp;\u003ci\u003edied\u003c/i\u003e before the\u0026nbsp;last scheduled follow up\n            \u003c/li\u003e\n        \u003c/ul\u003e\n    \u003c/li\u003e\n    \u003cli\u003e\n        Additional clinical phenotype data\n        \u003cul\u003e\n            \u003cli\u003e\n                Sex\n            \u003c/li\u003e\n            \u003cli\u003e\n                Race\n            \u003c/li\u003e\n            \u003cli\u003e\n                Cancer type*\n            \u003c/li\u003e\n            \u003cli\u003e\n                WHO grading**\n            \u003c/li\u003e\n        \u003c/ul\u003e\n    \u003c/li\u003e\n\u003c/ul\u003e\n\u003cp\u003e\n    *Brain cancer types include:\n\u003c/p\u003e\n\u003cul\u003e\n    \u003cli\u003e\n        \u003ci\u003eAstrocytoma\u003c/i\u003e\u0026nbsp;- Originates in a particular kind of glial cells called astrocytes, star-shaped brain cells in the cerebrum. This type of tumor does not usually spread outside the brain and spinal cord; it usually does not affect other organs.\n    \u003c/li\u003e\n    \u003cli\u003e\n        \u003ci\u003eGBM (glioblastoma)\u003c/i\u003e\u0026nbsp;- The most aggressive cancer that begins within the brain. Glioblastomas represent 15% of brain tumors. They can either start from normal glial cells or develop from an existing low-grade astrocytoma.\n    \u003c/li\u003e\n    \u003cli\u003e\n        \u003ci\u003eOligodendroglioma -\u003c/i\u003e\u0026nbsp;A tumor that can occur in the brain or spinal cord.\u0026nbsp; An oligodendroglioma tumor forms from oligodendrocytes — glial cells in the brain and spinal cord that produce myelin, a substance that protects nerve cells.\n    \u003c/li\u003e\n    \u003cli\u003e\n        \u003ci\u003eMixed\u003c/i\u003e\u0026nbsp;- A tumor that has a mixed etiology.\n    \u003c/li\u003e\n\u003c/ul\u003e\n\u003cp\u003e\n    **World Health Organization (WHO) grading is a measure of the “progressiveness” of central nervous system tumors:\n\u003c/p\u003e\n\u003cul\u003e\n    \u003cli\u003e\n        \u003ci\u003eII\u003c/i\u003e - A group of abnormal slow growing cells that are found only in the place where they first formed in the body, are somewhat infiltrative, and may recur as a higher grade\n    \u003c/li\u003e\n    \u003cli\u003e\n        \u003ci\u003eIII\u003c/i\u003e - Malignant and infiltrative cells that tend to recur as a higher grade\n    \u003c/li\u003e\n    \u003cli\u003e\n        \u003ci\u003eIV\u003c/i\u003e - The most malignant cells that experience rapid and aggressive growth and are widely infiltrative with rapid recurrence\n    \u003c/li\u003e\n\u003c/ul\u003e\n\u003cp\u003e\n    \u003cb\u003ePhase 1 Data Files (released November 1, 2019)\u003c/b\u003e\n\u003c/p\u003e\n\u003cul\u003e\n    \u003cli\u003e\n        Sub-challenge 1\n        \u003cul\u003e\n            \u003cli\u003e\n                \u003ca href=\"https://precision.fda.gov/home/files/file-GGGJjQ00Qqbbq0GvGbZXb36J-1\"\u003eOutcome (survival status)\u003c/a\u003e\n            \u003c/li\u003e\n            \u003cli\u003e\n                \u003ca href=\"https://precision.fda.gov/home/files/file-GGGJpKj0QqbYJPFVG5p7Kzfb-1\"\u003eClinical phenotypes\u003c/a\u003e\n            \u003c/li\u003e\n            \u003cli\u003e\n                \u003ca href=\"https://precision.fda.gov/home/files/file-GGGK0Qj0Qqby6K9z5v0zZzKp-1\"\u003eGene expression\u003c/a\u003e\n            \u003c/li\u003e\n        \u003c/ul\u003e\n    \u003c/li\u003e\n    \u003cli\u003e\n        Sub-challenge 2\n        \u003cul\u003e\n            \u003cli\u003e\n                \u003ca href=\"https://precision.fda.gov/home/files/file-GGGJxzj0QqbjYJ4GFjkKjFg2-1\"\u003eOutcome (survival status)\u003c/a\u003e\n            \u003c/li\u003e\n            \u003cli\u003e\n                \u003ca href=\"https://precision.fda.gov/home/files/file-GGGJxzQ0QqbQvP243kb3gJf4-1\"\u003eClinical phenotypes\u003c/a\u003e\n            \u003c/li\u003e\n            \u003cli\u003e\n                \u003ca href=\"https://precision.fda.gov/home/files/file-GGGJxzj0QqbpZx859JJxgb7Z-1\"\u003eDNA copy number\u003c/a\u003e\n            \u003c/li\u003e\n        \u003c/ul\u003e\n    \u003c/li\u003e\n    \u003cli\u003e\n        Sub-challenge 3\n        \u003cul\u003e\n            \u003cli\u003e\n                \u003ca href=\"https://precision.fda.gov/home/files/file-GGGJxz80QqbXjXqy5xB5YBJ9-1\"\u003eOutcome (survival status)\u003c/a\u003e\n            \u003c/li\u003e\n            \u003cli\u003e\n                \u003ca href=\"https://precision.fda.gov/home/files/file-GGGJy000QqbqV0pJ9Yj02z14-1\"\u003eClinical phenotypes\u003c/a\u003e\n            \u003c/li\u003e\n            \u003cli\u003e\n                \u003ca href=\"https://precision.fda.gov/home/files/file-GGGJxz80QqbVppkyBjGk7vXG-1\"\u003eGene expression and DNA copy number\u003c/a\u003e\n            \u003c/li\u003e\n        \u003c/ul\u003e\n    \u003c/li\u003e\n\u003c/ul\u003e\n\u003cp\u003e\n    \u003cb\u003ePhase 2 Data Files (Released February 7, 2020)\u003c/b\u003e\n\u003c/p\u003e\n\u003cp\u003e\n    The Phase 2 data will be released during the second stage of the challenge. Note that Outcome (survival status) will be withheld from Phase 2 files and participants will predict this value. The features selected and model obtained using the Phase 1 data in sub-challenges 1, 2 and 3 will be applied to the Phase 2 data to predict patient outcomes (survival status) for Phase 2. Participants are asked to run their models on the Phase 2 data only once as to avoid overfitting. These predicted values will be used to score the sub-challenges.\n\u003c/p\u003e\n\u003cul\u003e\n    \u003cli\u003e\n        Sub-challenge 1\n        \u003cul\u003e\n            \u003cli\u003e\n                Clinical phenotypes = \u003ca href=\"https://precision.fda.gov/home/files/file-Fjy20600jPqJ4PJv69GzY2Xq-1\"\u003esc1_Phase2_GE_Phenotype.tsv\u003c/a\u003e\n            \u003c/li\u003e\n            \u003cli\u003e\n                Gene expression = \u003ca href=\"https://precision.fda.gov/home/files/file-Fjy20600jPqPYqq9JVXvBpz8-1\"\u003esc1_Phase2_GE_FeatureMatrix.tsv\u003c/a\u003e\n            \u003c/li\u003e\n        \u003c/ul\u003e\n    \u003c/li\u003e\n    \u003cli\u003e\n        Sub-challenge 2\n        \u003cul\u003e\n            \u003cli\u003e\n                Clinical phenotypes = \u003ca href=\"https://precision.fda.gov/files/file-Fjy20600jPqKVZ9Z350ZvQGV-1\"\u003esc2_Phase2_CN_Phenotype.tsv\u003c/a\u003e\n            \u003c/li\u003e\n            \u003cli\u003e\n                DNA copy number = \u003ca href=\"https://precision.fda.gov/home/files/file-Fjy20600jPqB1xQf73Y7gJbq-1\"\u003esc2_Phase2_CN_FeatureMatrix.tsv\u003c/a\u003e\n            \u003c/li\u003e\n        \u003c/ul\u003e\n    \u003c/li\u003e\n    \u003cli\u003e\n        Sub-challenge 3\n        \u003cul\u003e\n            \u003cli\u003e\n                Clinical phenotypes = \u003ca href=\"https://precision.fda.gov/home/files/file-Fjy20600jPq5jxz8BVk6BB8z-1\"\u003esc3_Phase2_CN_GE_Phenotype.tsv\u003c/a\u003e\n            \u003c/li\u003e\n            \u003cli\u003e\n                Gene expression and DNA copy number = \u003ca href=\"https://precision.fda.gov/home/files/file-Fjy21ZQ0jPq500Vg2yx6bzvF-1\"\u003esc3_Phase2_CN_GE_FeatureMatrix.tsv\u003c/a\u003e\n            \u003c/li\u003e\n        \u003c/ul\u003e\n    \u003c/li\u003e\n\u003c/ul\u003e\n\u003ch2\u003e\n    SUBMISSION DETAILS\n\u003c/h2\u003e\n\u003cp\u003e\n    \u003cb\u003eChallenge timeline\u003c/b\u003e\n\u003c/p\u003e\n\u003cul\u003e\n    \u003cli\u003e\n        Phase 1\n        \u003cul\u003e\n            \u003cli\u003e\n                November 1, 2019: Phase 1 data released\n            \u003c/li\u003e\n            \u003cli\u003e\n                February 5, 2020: Deadline for phase 1 submissions, which must include:\n                \u003cul\u003e\n                    \u003cli\u003e\n                        Phase 1 model summary\n                    \u003c/li\u003e\n                    \u003cli\u003e\n                        Phase 1 data used\n                    \u003c/li\u003e\n                \u003c/ul\u003e\n            \u003c/li\u003e\n        \u003c/ul\u003e\n    \u003c/li\u003e\n    \u003cli\u003e\n        Phase 2\n        \u003cul\u003e\n            \u003cli\u003e\n                February 7, 2020: Phase 2 data released\n                \u003cul\u003e\n                    \u003cli\u003e\n                        Participants are expected to apply the models they have built using Phase 1 data to the Phase 2 data using gene expression, copy number, and clinical phenotype data (the latter is optional). This is expected to be done only once to avoid overfitting.\n                    \u003c/li\u003e\n                \u003c/ul\u003e\n            \u003c/li\u003e\n            \u003cli\u003e\n                February 14, 2020: Deadline for Phase 2 submissions, which must include:\n                \u003cul\u003e\n                    \u003cli\u003e\n                        Phase 2 model summary\n                    \u003c/li\u003e\n                    \u003cli\u003e\n                        Phase 2 sub-challenge 1 patient outcome predictions\n                    \u003c/li\u003e\n                    \u003cli\u003e\n                        Phase 2 sub-challenge 2 patient outcome predictions\n                    \u003c/li\u003e\n                    \u003cli\u003e\n                        Phase 2 sub-challenge 3 patient outcome predictions\n                    \u003c/li\u003e\n                \u003c/ul\u003e\n            \u003c/li\u003e\n        \u003c/ul\u003e\n    \u003c/li\u003e\n\u003c/ul\u003e\n\u003cp\u003e\n    \u003cb\u003eSubmission file format description\u003c/b\u003e\n\u003c/p\u003e\n\u003cp\u003e\n    \u003ci\u003ePhase 1 model summary\u003cbr\u003e\u003c/i\u003eThis document is meant to be a summary of the models used on the Phase 1 data. Provide the following details for EACH sub-challenge within “Summary-Phase1.txt”. Please use the provided \u003ca href=\"https://precision.fda.gov/files/file-Fg096380pkG7xXPp1b76Yxxq-1\"\u003etemplate\u003c/a\u003e.\u0026nbsp;\u003cbr\u003ea) Provide a description of model settings and parameters, and details of model building including dataset(s) description(s) used for training, cross validation and testing (number of samples, number of features, etc.)\u0026nbsp;\u003cbr\u003eb) Short listed features selected by the model\u003cbr\u003ec) Link to complete code in a public GitHub repository\u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; d)\u0026nbsp;Confusion matrix indicating number of predictions, true positives, false positives, true negatives, and false negatives\u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; e) Overall accuracy\u003cbr\u003ef) Specificity\u003cbr\u003eg) Sensitivity\u0026nbsp;\u003cbr\u003eh) Area under the curve (AUC)\n\u003c/p\u003e\n\u003cp\u003e\n    \u003ci\u003ePhase 1 data used\u003c/i\u003e\u003cbr\u003eA compressed file that includes the data files from each sub-challenge used for analysis so that step (a) above can be reproduced. This would be the final files used for analysis after any data transformation or other processing has been applied\n\u003c/p\u003e\n\u003cp\u003e\n    \u003ci\u003ePhase 2 model summary\u003c/i\u003e\u003cbr\u003eThis document is meant to provide a description of the settings used on the Phase 2 data to confirm the same model was utilized for Phase 1 and Phase 2.\u0026nbsp; Provide the model description for EACH sub-challenge within “Summary-Phase2.txt”. Please use the provided \u003ca href=\"https://precision.fda.gov/home/files/file-FfxVQ880jPqGKKz2PzpkZ4gP-1\"\u003etemplate\u003c/a\u003e.\n\u003c/p\u003e\n\u003cp\u003e\n    \u003ci\u003ePhase 2 sub-challenge 1 patient outcome predictions\u003c/i\u003e\u003cbr\u003eFor sub-challenge 1, participants are expected to apply the models they have built using Phase 1 to the Phase 2 sub-challenge 1 test data. The survival status outcome is to be predicted. Participants are required to submit a tab separated text file (TSV) named “subchallenge_1.tsv”.\u0026nbsp; Files are expected to follow Unix format. In this file each row represents the prediction for survival status for each patient in the Phase 2 dataset. The first column is the patient name, and the second column is either 0 or 1 indicting the outcome status (0 means the patient is alive or censoring at last follow up and 1 means patient died before the last scheduled follow up). An example is shown below:\u003cbr\u003ePATIENTID\u0026nbsp; \u0026nbsp;SURVIVAL_STATUS\u003cbr\u003ePatient_A \u0026nbsp; 0\u003cbr\u003ePatient_B \u0026nbsp; 1\u003cbr\u003ePatient_C \u0026nbsp; 1\n\u003c/p\u003e\n\u003cp\u003e\n    \u003ci\u003ePhase 2 sub-challenge 2 patient outcome predictions\u003c/i\u003e\u003cbr\u003eFor sub-challenge 2, participants are expected to apply the models they have built using Phase 1 to the Phase 2 sub-challenge 2 test data. The survival status outcome is to be predicted. Participants are required to submit a tab separated text file (TSV) named “subchallenge_2.tsv”. The format of the file is the same as the\u0026nbsp;Phase 2 sub-challenge 1 patient outcome predictions.\n\u003c/p\u003e\n\u003cp\u003e\n    \u003ci\u003ePhase 2 sub-challenge 3 patient outcome predictions\u003c/i\u003e\u003cbr\u003eFor sub-challenge 3, participants are expected to apply the models they have built using Phase 1 to the Phase 2 sub-challenge 3 test data. The survival status outcome is to be predicted. Participants are required to submit a tab separated text file (TSV) named “subchallenge_3.tsv”. The format of the file is the same as the Phase 2 sub-challenge 1 patient outcome predictions.\n\u003c/p\u003e\n\u003ch2\u003e\n    EVALUATION CRITERIA\n\u003c/h2\u003e\n\u003cul\u003e\n    \u003cli\u003e\n        The truth are the actual outcomes (survival status) for the patients in the Phase 2 data. These outcomes will be compared with the predicted values in Phase 2 for each sub-challenge submission. Models will be evaluated using metrics such as sensitivity, specificity, positive predictive value (precision),\u0026nbsp; F1-score, and diagnostic odds ratio.\n    \u003c/li\u003e\n    \u003cli\u003e\n        The use of a small set of features while maintaining model performance. The use of the phenotype (clinical) data is encouraged but optional. Participants are asked to make use of and describe feature selection techniques used.\n    \u003c/li\u003e\n\u003c/ul\u003e\n\u003ch2\u003e\n    CHALLENGE DISCUSSION\n\u003c/h2\u003e\n\u003cp\u003e\n    Please use \u003ca href=\"https://precision.fda.gov/discussions/63-the-brain-cancer-predictive-modeling-and-biomarker-discovery-challenge-discussion-forum\"\u003eThe Brain Cancer Predictive Modeling and Biomarker Discovery Challenge Discussion thread\u003c/a\u003e on the \u003ca href=\"https://precision.fda.gov/discussions\"\u003eprecisionFDA Discussions forum\u003c/a\u003e to discuss the challenge and ask questions.\n\u003c/p\u003e\n\u003ch2\u003e\n    FREQUENTLY ASKED QUESTIONS\n\u003c/h2\u003e\n\u003cul\u003e\n    \u003cli\u003e\n        Q: Can I participate in only one sub-challenge?\n        \u003cul\u003e\n            \u003cli\u003e\n                A: Yes. Participants can choose to participate in in only one sub-challenge, but are encouraged to participate in all three challenges as the total score is the sum of the predictions from all three sub-challenges.\n            \u003c/li\u003e\n        \u003c/ul\u003e\n    \u003c/li\u003e\n    \u003cli\u003e\n        Q: Can we participate and submit as a team?\n        \u003cul\u003e\n            \u003cli\u003e\n                A: Participants may submit as a team; however, they will need to appoint one member to request login access and to submit under that account.\n            \u003c/li\u003e\n        \u003c/ul\u003e\n    \u003c/li\u003e\n\u003c/ul\u003e\n\u003cul\u003e\n    \u003cli\u003e\n        Q:\u0026nbsp;Are participants allowed to use external datasets at any step of the challenge (model training and/or validation)?\n        \u003cul\u003e\n            \u003cli\u003e\n                Model training and validation challenge phases are restricted only to provided datasets.\n            \u003c/li\u003e\n        \u003c/ul\u003e\n    \u003c/li\u003e\n\u003c/ul\u003e\n\u003ch2\u003e\n    CHALLENGE TEAM\n\u003c/h2\u003e\n\u003cul\u003e\n    \u003cli\u003e\n        PrecisionFDA: Elaine Johanson, Ruth Bandler\n    \u003c/li\u003e\n    \u003cli\u003e\n        Georgetown University: Subha Madhavan, Yuriy Gusev, Adil Alaoui, Krithika Bhuvaneshwar\n    \u003c/li\u003e\n    \u003cli\u003e\n        Booz Allen: Holly Stephens, Sean Watford, Zeke Maier\n    \u003c/li\u003e\n\u003c/ul\u003e\n\u003ch2\u003e\n    REFERENCES\n\u003c/h2\u003e\n\u003cp\u003e\n    Staedtke, V., a Dzaye, O. D., \u0026amp; Holdhoff, M. (2016). Actionable molecular biomarkers in primary brain tumors. Trends in cancer, 2(7): 338-349.\n\u003c/p\u003e\n\u003cp\u003e\n    Song, L., Bhuvaneshwar, K., Wang, Y., Feng, Y., Shih, I-M., Madhavan, S., Gusev, Y. (2017). CINdex: A Bioconductor Package for Analysis of Chromosome Instability in DNA Copy Number Data. Cancer Inform., 16:1176935117746637 (PMID: 29343938).\n\u003c/p\u003e",
        "results": "\u003ch2 class=\"text-left\"\u003e\n    PrecisionFDA partnered with Georgetown University Lombardi Comprehensive Cancer Center and The Innovation Center for Biomedical Informatics (ICBI) to launch the Brain Cancer Predictive Modeling and Biomarker Discovery Challenge that ran from November 1, 2019 to February 14, 2020. This challenge asked participating teams to develop machine learning and/or artificial intelligence models to identify biomarkers to predict patient outcomes using DNA copy number, gene expression, and clinical data. In total, there were 30 submissions from 28 teams submitted for Phase 1, and 22 submissions from 22 teams for Phase 2 encompassing a wide range of models.\n\u003c/h2\u003e",
        "results-details": "\u003cp\u003e\n    Results are displayed and discussed below. As with previous challenges, these results offer a first glance at our understanding. We welcome the community to further explore these results and provide additional insights for the future.\n\u003c/p\u003e\n\u003ch1\u003e\n    Introductory Remarks\n\u003c/h1\u003e\n\u003cp\u003e\n    In this challenge, participating teams were asked to take part in three sub-challenges, which would be scored individually and combined for an overall challenge score. They were provided DNA copy number data, gene expression profiles, clinical phenotypes, and outcomes for a cohort of patients.\n\u003c/p\u003e\n\u003cp\u003e\n    The data for the challenge was released in two phases – Phase 1 and Phase 2. The Phase 1 data was the provided data that would be used to develop the models. Phase 2 data was the test data that would be used to score model performance. The truth are the actual outcomes (survival status) for the patients in the Phase 2 data that were withheld from participants. These outcomes would be compared with the predicted values in Phase 2 for each sub-challenge submission. The models would be evaluated using metrics such as sensitivity, specificity, and accuracy.\n\u003c/p\u003e\n\u003cp\u003e\n    In summary, Phase 1 and 2 included the following sub-challenges:\n\u003c/p\u003e\n\u003cul\u003e\n    \u003cli\u003e\n        Sub-challenge 1 – Gene expression\n    \u003c/li\u003e\n    \u003cli\u003e\n        Sub-challenge 2 – DNA copy number\n    \u003c/li\u003e\n    \u003cli\u003e\n        Sub-challenge 3 – Gene expression and DNA copy number combined\n    \u003c/li\u003e\n\u003c/ul\u003e\n\u003cp\u003e\n    The goal of this challenge was to develop models that are focused on integration of molecular data of two types including gene expression, copy number, and clinical phenotype data to better predict clinical outcome.\n\u003c/p\u003e\n\u003ch1\u003e\n    Overview of Results\n\u003c/h1\u003e\n\u003cp\u003e\n    The challenge went live on Nov 1, 2019, and Phase 1 ran until February 5, 2020. The Phase 2 data was then released on February 7, 2020 and the challenge submission period closed February 14, 2020. The truth are the actual outcomes (survival status) for the patients in the Phase 2 data. These outcomes would be compared with the predicted values in Phase 2 for each sub-challenge submission. The models would be evaluated using metrics such as sensitivity, specificity, and accuracy.\n\u003c/p\u003e\n\u003cp\u003e\n    We received a total of 30 submissions from participating teams for Phase 1. These included 30 submissions from 28 participating teams since some teams submitted more than once. We received a total of 22 submissions from participating teams for Phase 2 that included a wide range of machine learning models.\u0026nbsp;\u003cb\u003eTable 1\u003c/b\u003e shows a summary of the different types of models used in Sub-challenge 3 (SC3) by the participating teams.\n\u003c/p\u003e\n\u003cp class=\"text-left\"\u003e\n    \u003ci\u003eTable 1: Summary of the different types\u0026nbsp;of models submitted for Sub-challenge 3\u003c/i\u003e\n\u003c/p\u003e\n\u003ctable border=\"1\"\u003e\n    \u003cthead\u003e\n        \u003ctr\u003e\n            \u003cth\u003e\n                Name of Model\n            \u003c/th\u003e\n            \u003cth\u003e\n                Number of Submissions\n            \u003c/th\u003e\n        \u003c/tr\u003e\n    \u003c/thead\u003e\n    \u003ctbody\u003e\n        \u003ctr\u003e\n            \u003ctd\u003e\n                Gradient Boosting Framework\n            \u003c/td\u003e\n            \u003ctd class=\"text-center\"\u003e\n                6\n            \u003c/td\u003e\n        \u003c/tr\u003e\n        \u003ctr\u003e\n            \u003ctd\u003e\n                Neural Networks\n            \u003c/td\u003e\n            \u003ctd class=\"text-center\"\u003e\n                1\n            \u003c/td\u003e\n        \u003c/tr\u003e\n        \u003ctr\u003e\n            \u003ctd\u003e\n                Support Vector Machine\n            \u003c/td\u003e\n            \u003ctd class=\"text-center\"\u003e\n                3\n            \u003c/td\u003e\n        \u003c/tr\u003e\n        \u003ctr\u003e\n            \u003ctd\u003e\n                Logistic Regression\n            \u003c/td\u003e\n            \u003ctd class=\"text-center\"\u003e\n                3\n            \u003c/td\u003e\n        \u003c/tr\u003e\n        \u003ctr\u003e\n            \u003ctd\u003e\n                Ensemble Model\n            \u003c/td\u003e\n            \u003ctd class=\"text-center\"\u003e\n                4\n            \u003c/td\u003e\n        \u003c/tr\u003e\n        \u003ctr\u003e\n            \u003ctd\u003e\n                Generalized Linear Model (GLM)\n            \u003c/td\u003e\n            \u003ctd class=\"text-center\"\u003e\n                2\n            \u003c/td\u003e\n        \u003c/tr\u003e\n        \u003ctr\u003e\n            \u003ctd\u003e\n                Naive Bayes\n            \u003c/td\u003e\n            \u003ctd class=\"text-center\"\u003e\n                1\n            \u003c/td\u003e\n        \u003c/tr\u003e\n        \u003ctr\u003e\n            \u003ctd\u003e\n                K-Nearest Neighbors Algorithm\n            \u003c/td\u003e\n            \u003ctd class=\"text-center\"\u003e\n                1\n            \u003c/td\u003e\n        \u003c/tr\u003e\n        \u003ctr\u003e\n            \u003ctd\u003e\n                Random Forest\n            \u003c/td\u003e\n            \u003ctd class=\"text-center\"\u003e\n                1\n            \u003c/td\u003e\n        \u003c/tr\u003e\n    \u003c/tbody\u003e\n\u003c/table\u003e\n\u003ch2\u003e\n    Evaluation\n\u003c/h2\u003e\n\u003cp\u003e\n    Our goal was to rank participant teams whose models provided a short list of the most informative features for brain cancer. We developed an evaluation algorithm that would automatically rank the Phase 2 submissions based on three metrics – accuracy, sensitivity and specificity. In each sub-challenge, each metric was ranked individually. For instance, the participating team with the highest accuracy in Sub-challenge 1 was given a rank of 1 for the accuracy metric and so on. The sum of the ranks were taken to obtain a final score in Sub-challenge 1. Similarly, the sum of the ranks for Sub-challenges 2 and 3 were calculated. The best possible score for a sub-challenge is 3, which means the submission was the top rank (i.e., 1) for accuracy, sensitivity, and specificity. The worst possible score for a sub-challenge is 66, which means the submission was the lowest rank (i.e., 22) for accuracy, sensitivity, and specificity.\n\u003c/p\u003e\n\u003cp\u003e\n    The overall score was obtained using this formula: \u003ci\u003eOverall score\u0026nbsp;\u003c/i\u003e= SC\u003ci\u003e1 score\u0026nbsp;\u003c/i\u003e+\u003ci\u003e\u0026nbsp;SC2 score\u0026nbsp;\u003c/i\u003e+ (2 × SC\u003ci\u003e3 score\u003c/i\u003e). Sub-challenge 3 (SC3) was given twice the importance as Sub-challenge 1 (SC1) and Sub-challenge 2 (SC2) since it contained multiple data types including gene expression, copy number, and clinical phenotype data, which made the model building and prediction more complex. The best possible overall score is 12, and the worst possible overall score is 264.\n\u003c/p\u003e\n\u003ch2\u003e\n    Results\n\u003c/h2\u003e\n\u003cp\u003e\n    The top performers selected by the automated algorithm are summarized in \u003cb\u003eTable 2\u003c/b\u003e.\n\u003c/p\u003e\n\u003cp class=\"text-left\"\u003e\n    \u003ci\u003eTable 2. Summary of the top performers\u003c/i\u003e\n\u003c/p\u003e\n\u003ctable border=\"1\"\u003e\n    \u003cthead\u003e\n        \u003ctr\u003e\n            \u003cth class=\"text-left\"\u003e\n                Rank\n            \u003c/th\u003e\n            \u003cth class=\"text-left\"\u003e\n                Team\n            \u003c/th\u003e\n            \u003cth class=\"text-left\"\u003e\n                Username\n            \u003c/th\u003e\n            \u003cth\u003e\n                Sub-challenge 1 Rank\n            \u003c/th\u003e\n            \u003cth\u003e\n                Sub-challenge 2 Rank\n            \u003c/th\u003e\n            \u003cth\u003e\n                Sub-challenge 3 Rank\n            \u003c/th\u003e\n            \u003cth\u003e\n                Overall Score\n            \u003c/th\u003e\n        \u003c/tr\u003e\n    \u003c/thead\u003e\n    \u003ctbody\u003e\n        \u003ctr\u003e\n            \u003ctd\u003e\n                1\n            \u003c/td\u003e\n            \u003ctd\u003e\n                Sentieon*\n            \u003c/td\u003e\n            \u003ctd\u003e\n                hanying.feng\n            \u003c/td\u003e\n            \u003ctd class=\"text-center\"\u003e\n                19\n            \u003c/td\u003e\n            \u003ctd class=\"text-center\"\u003e\n                8\n            \u003c/td\u003e\n            \u003ctd class=\"text-center\"\u003e\n                5\n            \u003c/td\u003e\n            \u003ctd class=\"text-center\"\u003e\n                37\n            \u003c/td\u003e\n        \u003c/tr\u003e\n        \u003ctr\u003e\n            \u003ctd\u003e\n                1\n            \u003c/td\u003e\n            \u003ctd\u003e\n                Sentieon*\n            \u003c/td\u003e\n            \u003ctd\u003e\n                hanying.feng\n            \u003c/td\u003e\n            \u003ctd class=\"text-center\"\u003e\n                12\n            \u003c/td\u003e\n            \u003ctd class=\"text-center\"\u003e\n                12\n            \u003c/td\u003e\n            \u003ctd class=\"text-center\"\u003e\n                17\n            \u003c/td\u003e\n            \u003ctd class=\"text-center\"\u003e\n                58\n            \u003c/td\u003e\n        \u003c/tr\u003e\n        \u003ctr\u003e\n            \u003ctd\u003e\n                2\n            \u003c/td\u003e\n            \u003ctd\u003e\n                Seven Bridges Genomics**\n            \u003c/td\u003e\n            \u003ctd\u003e\n                nan.xiao\n            \u003c/td\u003e\n            \u003ctd class=\"text-center\"\u003e\n                49\n            \u003c/td\u003e\n            \u003ctd class=\"text-center\"\u003e\n                18\n            \u003c/td\u003e\n            \u003ctd class=\"text-center\"\u003e\n                12\n            \u003c/td\u003e\n            \u003ctd class=\"text-center\"\u003e\n                91\n            \u003c/td\u003e\n        \u003c/tr\u003e\n        \u003ctr\u003e\n            \u003ctd\u003e\n                3\n            \u003c/td\u003e\n            \u003ctd\u003e\n                Gnosis DA***\n            \u003c/td\u003e\n            \u003ctd\u003e\n                konstantinos.paraschakis\n            \u003c/td\u003e\n            \u003ctd class=\"text-center\"\u003e\n                24\n            \u003c/td\u003e\n            \u003ctd class=\"text-center\"\u003e\n                34\n            \u003c/td\u003e\n            \u003ctd class=\"text-center\"\u003e\n                20\n            \u003c/td\u003e\n            \u003ctd class=\"text-center\"\u003e\n                98\n            \u003c/td\u003e\n        \u003c/tr\u003e\n        \u003ctr\u003e\n            \u003ctd\u003e\n                4\n            \u003c/td\u003e\n            \u003ctd\u003e\n                Aginome-AmoyDx-XMU****\n            \u003c/td\u003e\n            \u003ctd\u003e\n                xu.canqiang\n            \u003c/td\u003e\n            \u003ctd class=\"text-center\"\u003e\n                28\n            \u003c/td\u003e\n            \u003ctd class=\"text-center\"\u003e\n                24\n            \u003c/td\u003e\n            \u003ctd class=\"text-center\"\u003e\n                25\n            \u003c/td\u003e\n            \u003ctd class=\"text-center\"\u003e\n                102\n            \u003c/td\u003e\n        \u003c/tr\u003e\n        \u003ctr\u003e\n            \u003ctd\u003e\n                5\n            \u003c/td\u003e\n            \u003ctd\u003e\n                Rintu Kutum\n            \u003c/td\u003e\n            \u003ctd\u003e\n                rintu.kutum\n            \u003c/td\u003e\n            \u003ctd class=\"text-center\"\u003e\n                31\n            \u003c/td\u003e\n            \u003ctd class=\"text-center\"\u003e\n                36\n            \u003c/td\u003e\n            \u003ctd class=\"text-center\"\u003e\n                18\n            \u003c/td\u003e\n            \u003ctd class=\"text-center\"\u003e\n                103\n            \u003c/td\u003e\n        \u003c/tr\u003e\n        \u003ctr\u003e\n            \u003ctd\u003e\n                Best Possible Score\n            \u003c/td\u003e\n            \u003ctd\u003e\n                \n            \u003c/td\u003e\n            \u003ctd\u003e\n                \n            \u003c/td\u003e\n            \u003ctd class=\"text-center\"\u003e\n                3\n            \u003c/td\u003e\n            \u003ctd class=\"text-center\"\u003e\n                3\n            \u003c/td\u003e\n            \u003ctd class=\"text-center\"\u003e\n                3\n            \u003c/td\u003e\n            \u003ctd class=\"text-center\"\u003e\n                12\n            \u003c/td\u003e\n        \u003c/tr\u003e\n        \u003ctr\u003e\n            \u003ctd\u003e\n                Worst Possible Score\n            \u003c/td\u003e\n            \u003ctd\u003e\n                \n            \u003c/td\u003e\n            \u003ctd\u003e\n                \n            \u003c/td\u003e\n            \u003ctd class=\"text-center\"\u003e\n                66\n            \u003c/td\u003e\n            \u003ctd class=\"text-center\"\u003e\n                66\n            \u003c/td\u003e\n            \u003ctd class=\"text-center\"\u003e\n                66\n            \u003c/td\u003e\n            \u003ctd class=\"text-center\"\u003e\n                264\n            \u003c/td\u003e\n        \u003c/tr\u003e\n    \u003c/tbody\u003e\n\u003c/table\u003e\n\u003cp class=\"text-left\"\u003e\n    \u003ci\u003e*Hanying Feng, Hong Chen, Luoqi Chen, and Jun Ye\u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp;**Nan Xiao, Soner Koc, and Kaushik Ghose\u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; ***Konstantinos Parachakis, and team lead Ioannis Tsamardinos\u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp;****Canqiang Xu,\u0026nbsp;Wenxian Yang,\u0026nbsp;Frank Zheng, and\u0026nbsp;Rongshan Yu\u003c/i\u003e\n\u003c/p\u003e\n\u003cp\u003e\n    We also explored trends for each sub-challenge. \u003cb\u003eFigure 1\u003c/b\u003e\u0026nbsp;shows a stacked line graph of the scores in each sub-challenge, and the overall score. The submissions are ordered on the overall scores, with the highest rank (top performer) on the left side.\n\u003c/p\u003e\n\u003cimg height=\"517\" src=\"https://dl.dnanex.us/F/D/GxxgKP36P095x9Z550Vk1XjXxY4640Z2zq2qJ53q/GW_results_Fig_1.PNG\" width=\"716\"\u003e\n\u003cp\u003e\n    \u003cb\u003eFigure 2\u003c/b\u003e shows the distribution of overall scores. Since the overall score is essentially derived from a rank, the best score is the one with the lowest value. To better understand this overall score, and for ease of understanding, we calculated normalized overall score using the following formula:\n\u003c/p\u003e\n\u003cimg height=\"43\" src=\"https://dl.dnanex.us/F/D/GVfxFfFGYkXqkXJbKQKFJk0xpqFV2xKqY14X5F7f/GW_formula.PNG\" width=\"537\"\u003e\n\u003cimg height=\"363\" src=\"https://dl.dnanex.us/F/D/9KYb9v5vFKz24Yf9PPz0PP4Pq8zJzq0v83K1yz49/GW_results_Fig_2.PNG\" width=\"702\"\u003e\n\u003cp\u003e\n    \u003cb\u003eFigure 3\u003c/b\u003e\u0026nbsp;shows the normalized overall score across all the submissions. The submissions are ordered based on the rank from left to right.\n\u003c/p\u003e\n\u003cimg height=\"367\" src=\"https://dl.dnanex.us/F/D/Pq0ZfXBz9f8Pv2Ff79bJ4Kp9Y2J541Jgb6f235Xj/Georgetown_Figure_3.PNG\" width=\"736\"\u003e\n\u003ch2\u003e\n    Top Performer\n\u003c/h2\u003e\n\u003cp\u003e\n    The top performer of the challenge was the participating team with the highest rank i.e., the lowest overall score\u003cb\u003e Sentieon*.\u003c/b\u003e This participating team had a total of 46 features selected in this model from SC3 including 40 genes, 4 cytobands and 2 clinical attributes.\n\u003c/p\u003e\n\u003ch1\u003e\n    Take-Aways and Lessons Learned\n\u003c/h1\u003e\n\u003cul\u003e\n    \u003cli\u003e\n        In SC1 and SC3, the participating teams were challenged with a large p, small n issue i.e., large number of features (approximately 20,000), and a small number of data points. The teams had to find solutions to not only find a way to select the most important features, but also deal with a potential overfitting challenge as a result of this imbalance. Another challenge the teams faced in all three sub-challenges was that the survival outcome status was imbalanced. For instance, in SC3, 76% of the patients were deceased. Many participating teams tried multi-layered models to deal with these challenges, wherein they would use a set of models for feature selection, another set of models for model building, and choose the best performing model as the final model.\n    \u003c/li\u003e\n    \u003cli\u003e\n        SC2 was more challenging than SC1 because DNA copy number was more complex to model compared to gene expression data\n    \u003c/li\u003e\n    \u003cli\u003e\n        SC3 was more challenging than SC2 and SC1 since there are multiple data types including gene expression, DNA copy number, and clinical phenotype data to model in conjunction with clinical outcome\n    \u003c/li\u003e\n\u003c/ul\u003e\n\u003ch1\u003e\n    Achievements\n\u003c/h1\u003e\n\u003cul\u003e\n    \u003cli\u003e\n        22 models were developed and applied to REMBRANDT Brain Cancer collection\n    \u003c/li\u003e\n    \u003cli\u003e\n        Several Models reached high accuracy of predictions of clinical outcome based on integration of molecular profiling data and clinical attributes\n    \u003c/li\u003e\n    \u003cli\u003e\n        Machine learning algorithms generated short lists of most informative features (genes, cytobands, and clinical attributes) that contain promising candidate biomarkers\n    \u003c/li\u003e\n\u003c/ul\u003e\n\u003ch1\u003e\n    Scientific Manuscript\n\u003c/h1\u003e\n\u003cp\u003e\n    The challenge team is planning to author a manuscript, along with the top performers of the challenge. It would provide an overview of the challenge data and design, and a summary of the submissions from various participating teams. Publication of the manuscript will be contingent on a standard evaluation process including editorial assessment and peer review. The data along with the submitted algorithms, including the winning algorithm, would be shared with the research community.\n\u003c/p\u003e\n\u003cp\u003e\n    The top 3 performers will be invited to present a podium presentation and poster at the 9th Annual Health Informatics and Data Science Symposium to be held in October at Georgetown University. This collaborative effort with the FDA could enable further discoveries and new hypotheses in translational research through science and open data and algorithm approaches.\n\u003c/p\u003e\n\u003ch1\u003e\n    Extra Credit Badges\n\u003c/h1\u003e\n\u003cp\u003e\n    In addition to the evaluation algorithm, badges were awarded to the top 5 performing teams based on overall score based on the several criteria outlined below.\n\u003c/p\u003e\n\u003cul\u003e\n    \u003cli\u003e\n        \u003cb\u003eModel robustness\u003c/b\u003e. This badge was awarded for participating teams that had specificity more than 0.5 and/or for using advanced modeling techniques in SC3\n    \u003c/li\u003e\n    \u003cli\u003e\n        \u003cb\u003eExtra credit based on short listed features, for potential use in biomarker research\u003c/b\u003e. This extra credit was awarded for using a solution that selected a short list of features out of more than 20,000 features. This short list of features has the potential to be used in biomarker discovery-based applications.\n    \u003c/li\u003e\n    \u003cli\u003e\n        \u003cb\u003eExtra Credit for utilizing domain knowledge i.e., clinical and/or biological/phenotypic information.\u003c/b\u003e This badge was awarded to those teams that did specialized curation or feature selection based on domain knowledge. We know that using machine learning models in conjunction with domain knowledge lends itself to superior models in bioinformatics.\n    \u003c/li\u003e\n    \u003cli\u003e\n        \u003cb\u003eOverall documentation, usability and overall presentation of results.\u003c/b\u003e\n    \u003c/li\u003e\n\u003c/ul\u003e\n\u003cp\u003e\n    \u003ci\u003eTable 3. Badges awarded to the top 5 performing teams\u003c/i\u003e\n\u003c/p\u003e\n\u003cimg height=\"563\" src=\"https://dl.dnanex.us/F/D/ByQvG3qg7q6kjJ8827jQ1P709jGgZQgbqVY7BJJX/ICBI%20BADGE%20MATRIX_top%205_gold_5212020.png\" width=\"951\"\u003e"
      }
    },
    "start_at": "2019-11-01T16:00:00.000Z",
    "end_at": "2020-02-15T04:59:59.000Z",
    "created_at": "2019-10-23T17:52:46.000Z",
    "updated_at": "2022-09-07T18:42:40.000Z",
    "status": "archived",
    "card_image_url": "https://dl.dnanex.us/F/D/7FB304PV456670P7BZb9pVB35KqPQKFpQvgqQkj7/ICBI_BrainTumorBiomarkerFigure_100719.png",
    "card_image_id": "file-Ffj96P006B2XYg9V45F872G0-1",
    "pre_registration_url": null,
    "links": null,
    "is_followed": null,
    "can_edit": null,
    "is_space_member": null
  }
}
